Harvard Bioscience completes regenerative medicine device spin-off

Harvard Bioscience (HBIO) is off 16% premarket after completing a spin-off of its regenerative medicine device subsidiary.

Harvard Apparatus Regenerative Technology now trades on the Nasdaq under the ticker HART.

HBIO shareholders got one share of HART for every share of HBIO they owned as of October 21.

HBIO now calls itself a "pure-play global developer, manufacturer and marketer of a broad range of tools to advance life science research." (PR)

CEO Jeffrey Duchemin has been appointed President and Director, replacing David Green who is now HART's President.

Comments (6)
  • mr.investor
    , contributor
    Comments (67) | Send Message
    I think some of this information is inaccurate. I owned 800 shares of HBIO up until close of business on October 22nd. I did not receive any shares of HART.
    4 Nov 2013, 08:52 AM Reply Like
  • gatlingg
    , contributor
    Comments (380) | Send Message
    1 share of HART for every 4 shares of HBIO they owned
    4 Nov 2013, 08:58 AM Reply Like
  • futureguy
    , contributor
    Comments (12) | Send Message
    I did hold till 31st Oct but have not received any shares yet
    4 Nov 2013, 09:40 AM Reply Like
  • idkmybffjill
    , contributor
    Comments (1874) | Send Message
    Why the sell-off in HBIO? Buying opp?!
    4 Nov 2013, 09:51 AM Reply Like
  • Elias Simpson
    , contributor
    Comments (44) | Send Message


    it's not exactly a sell off. the capitalization value is less because the company no longer includes HART.


    considering the distribution of HART shares at 1:4, HART market cap should be worth 20% that of HBIO. Respectively, HBIO would be worth 20% less now than before.


    i am long--but wouldn't buy HBIO right now. statistically speaking, spinoffs do better than the parent company post-split.
    5 Nov 2013, 09:50 PM Reply Like
  • idkmybffjill
    , contributor
    Comments (1874) | Send Message
    Not always Elias. Usually, but not always.


    In this case, the parent company's profitability was masked by the spinoff's lack of profitability.
    6 Nov 2013, 08:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs